1. A synergistic combination of antibodies specific for CD19, comprising an antibody that cross-competes with an antibody comprising HCDR1 with portion SYVMH sequence (SEQ ID NO: 1), HCDR2 portion with NPYNDG sequence (SEQ ID NO: 2), HCDR3 site with the sequence GTYYYGTRVFDY (SEQ ID NO: 3), LCDR1 portion with RSSKSLQNVNGNTYLY sequence (SEQ ID NO: 4), LCDR2 portion of sequence RMSNLNS (SEQ ID NO: 5) and LCDR3 portion of sequence MQHLEYPIT (SEQ ID NO: 6) and bendamustine for use in treating non-Hodgkins lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leykoza.2. A combination according to claim 1, wherein the antibody comprises an antibody that binds to the same epitope as an antibody comprising HCDR1 portion of sequence SYVMH (SEQ ID NO: 1)., HCDR2 portion with NPYNDG sequence (SEQ ID NO: 2 ), HCDR3 portion of sequence GTYYYGTRVFDY (SEQ ID NO: 3), LCDR1 portion with RSSKSLQNVNGNTYLY sequence (SEQ ID NO: 4), LCDR2 portion with RMSNLNS sequence (SEQ ID NO: 5) and LCDR3 portion with MQHLEYPIT (SEQ ID NO sequence 6) .3. A combination according to claim 1 or 2, characterized in that the antibody comprises HCDR1 portion with SYVMH sequence (SEQ ID NO: 1)., HCDR2 portion with NPYNDG sequence (SEQ ID NO: 2), HCDR3 portion with GTYYYGTRVFDY sequence (SEQ ID NO: 3), LCDR1 portion with RSSKSLQNVNGNTYLY sequence (SEQ ID NO: 4), LCDR2 portion of sequence RMSNLNS (SEQ ID NO: 5) and LCDR3 portion of sequence MQHLEYPIT (SEQ ID NO: 6) .4. A combination according to claim 1, wherein the antibody comprises a heavy chain variable region with posledovatelnostyuEVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS (SEQ ID NO: 10)., And light chain variable region with posledovatelnostyuDIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMS1. Синергическая комбинация антитела, специфичного к CD19, включающего антитело, которое перекрестно конкурирует с антителом, содержащим участок HCDR1 с последовате
